secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001641172-25-005772
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals' topical Ketamir-2 shows successful drug release in IVRT study
--------------------------------------------------------------------------------

- Topical Ketamir-2 demonstrated dose-proportional release in in vitro release testing, enabling non-opioid pain therapy.
- Preclinical efficacy studies in inflammatory and neuropathic pain models to begin shortly.
- Company evaluating Fast Track designation with FDA; U.S. topical pain relief market projected >$11.5B in 2025.
- Oral Ketamir-2 in Phase 1 trial; Phase 2a for diabetic neuropathy expected later in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225005772/0001641172-25-005772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225005772/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer